Jezper / Shutterstock.com
In-house counsel face daily challenges when managing and maintaining their IP portfolios. LSIPR asked two in-house counsel for the biggest challenges they face when managing and maintaining their IP portfolios. Here are the five things we learned.
1) Different patentability standards
In some countries it’s very difficult, if not impossible, to get claims that include ranges of sequence identity, warns Kamrin MacKnight, chief patent counsel at protein engineering company Codexis.
“We’re stuck with claims that cover only a specific sequence. That makes it much easier for competitors to design around our patents, as all they have to do is change one amino acid,” says MacKnight.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
IP portfolios, patentability, amino acid, US Supreme Court, biotech, DNA, IP counsel, European Patent Office, USPTO, IPRs, inventions, litigation